275 related articles for article (PubMed ID: 31337401)
1. Tryptophan catabolism increases in breast cancer patients compared to healthy controls without affecting the cancer outcome or response to chemotherapy.
Onesti CE; Boemer F; Josse C; Leduc S; Bours V; Jerusalem G
J Transl Med; 2019 Jul; 17(1):239. PubMed ID: 31337401
[TBL] [Abstract][Full Text] [Related]
2. Serum tryptophan and kynurenine concentrations as parameters for indoleamine 2,3-dioxygenase activity in patients with endometrial, ovarian, and vulvar cancer.
de Jong RA; Nijman HW; Boezen HM; Volmer M; Ten Hoor KA; Krijnen J; van der Zee AG; Hollema H; Kema IP
Int J Gynecol Cancer; 2011 Oct; 21(7):1320-7. PubMed ID: 21720257
[TBL] [Abstract][Full Text] [Related]
3. Mass spectrometric measurement of urinary kynurenine-to-tryptophan ratio in children with and without urinary tract infection.
Yarbrough ML; Briden KE; Mitsios JV; Weindel AL; Terrill CM; Hunstad DA; Dietzen DJ
Clin Biochem; 2018 Jun; 56():83-88. PubMed ID: 29679555
[TBL] [Abstract][Full Text] [Related]
4. Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer.
Suzuki Y; Suda T; Furuhashi K; Suzuki M; Fujie M; Hahimoto D; Nakamura Y; Inui N; Nakamura H; Chida K
Lung Cancer; 2010 Mar; 67(3):361-5. PubMed ID: 19487045
[TBL] [Abstract][Full Text] [Related]
5. Peripheral kynurenine/tryptophan ratio is not a reliable marker of systemic indoleamine 2,3-dioxygenase: A lesson drawn from patients on hemodialysis.
Chen Y; Xie Z; Xiao C; Zhang M; Li Z; Xie J; Zhang Y; Zhao X; Zeng P; Mo L; Liang X; Shi W
Oncotarget; 2017 Apr; 8(15):25261-25269. PubMed ID: 28445957
[TBL] [Abstract][Full Text] [Related]
6. Kynurenine/Tryptophan Ratio as a Potential Blood-Based Biomarker in Non-Small Cell Lung Cancer.
Mandarano M; Orecchini E; Bellezza G; Vannucci J; Ludovini V; Baglivo S; Tofanetti FR; Chiari R; Loreti E; Puma F; Sidoni A; Belladonna ML
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922388
[TBL] [Abstract][Full Text] [Related]
7. [Indoleamine 2, 3-dioxygenase activity during neoadjuvant chemotherapy in patients with breast cancer].
Sakurai K; Fujisaki S; Nagashima S; Maeda T; Tomita R; Suzuki S; Hara Y; Hirano T; Enomoto K; Amano S
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1578-80. PubMed ID: 24393854
[TBL] [Abstract][Full Text] [Related]
8. [Indoleamine 2,3-dioxygenase activity during chemotherapy in patients with breast cancer].
Sakurai K; Matsuo S; Enomoto K; Tani M; Kitajima A; Amano S
Gan To Kagaku Ryoho; 2009 Nov; 36(12):1991-3. PubMed ID: 20037301
[TBL] [Abstract][Full Text] [Related]
9. [Indoleamine 2,3-dioxygenase activity during chemotherapy or hormone therapy in patients with breast cancer].
Sakurai K; Enomoto K; Amano S
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2252-4. PubMed ID: 21224538
[TBL] [Abstract][Full Text] [Related]
10. Enhanced tryptophan-kynurenine metabolism via indoleamine 2,3-dioxygenase 1 induction in dermatomyositis.
Wu D; Chen M; Chen S; Zhang S; Chen Y; Zhao Q; Xue K; Xue F; Chen X; Zhou M; Li H; Zheng J; Le Y; Cao H
Clin Rheumatol; 2022 Oct; 41(10):3107-3117. PubMed ID: 35778590
[TBL] [Abstract][Full Text] [Related]
11. High Indoleamine 2,3-Dioxygenase Is Correlated With Microvessel Density and Worse Prognosis in Breast Cancer.
Wei L; Zhu S; Li M; Li F; Wei F; Liu J; Ren X
Front Immunol; 2018; 9():724. PubMed ID: 29719533
[TBL] [Abstract][Full Text] [Related]
12. Serum activity of indoleamine 2,3-dioxygenase predicts prognosis of community-acquired pneumonia.
Suzuki Y; Suda T; Yokomura K; Suzuki M; Fujie M; Furuhashi K; Hahimoto D; Enomto N; Fujisawa T; Nakamura Y; Inui N; Nakano Y; Nakamura H; Chida K
J Infect; 2011 Sep; 63(3):215-22. PubMed ID: 21784100
[TBL] [Abstract][Full Text] [Related]
13. Tryptophan metabolism to kynurenine is a potential novel contributor to hypotension in human sepsis.
Changsirivathanathamrong D; Wang Y; Rajbhandari D; Maghzal GJ; Mak WM; Woolfe C; Duflou J; Gebski V; dos Remedios CG; Celermajer DS; Stocker R
Crit Care Med; 2011 Dec; 39(12):2678-83. PubMed ID: 21765346
[TBL] [Abstract][Full Text] [Related]
14. Indoleamine 2,3-dioxygenase gene expression and kynurenine to tryptophan ratio correlation with nasopharyngeal carcinoma progression and survival.
Souissi S; Ghedira R; Macherki Y; Ben-Haj-Ayed A; Gabbouj S; Remadi Y; Sfar I; Chadli Z; Aouam K; Hassine M; Bouaouina N; Zakhama A; Hassen E
Immun Inflamm Dis; 2022 Sep; 10(9):e690. PubMed ID: 36039641
[TBL] [Abstract][Full Text] [Related]
15. Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1.
Botticelli A; Mezi S; Pomati G; Cerbelli B; Cerbelli E; Roberto M; Giusti R; Cortellini A; Lionetto L; Scagnoli S; Zizzari IG; Nuti M; Simmaco M; Marchetti P
Front Immunol; 2020; 11():1243. PubMed ID: 32733441
[No Abstract] [Full Text] [Related]
16. [Indoleamine 2,3-dioxygenase expression in breast cancer patients during chemotherapy].
Sakurai K; Enomoto K; Kitajima A; Tani M; Amano S; Shiono M
Gan To Kagaku Ryoho; 2008 Nov; 35(12):2265-7. PubMed ID: 19106591
[TBL] [Abstract][Full Text] [Related]
17. Up-regulation of indoleamine 2,3-dioxygenase 1 (IDO1) expression and catalytic activity is associated with immunosuppression and poor prognosis in penile squamous cell carcinoma patients.
Zhou QH; Han H; Lu JB; Liu TY; Huang KB; Deng CZ; Li ZS; Chen JP; Yao K; Qin ZK; Liu ZW; Li YH; Guo SJ; Ye YL; Zhou FJ; Liu RY
Cancer Commun (Lond); 2020 Jan; 40(1):3-15. PubMed ID: 32125093
[TBL] [Abstract][Full Text] [Related]
18. Activation of the Serotonin Pathway is Associated with Poor Outcome in COPD Exacerbation: Results of a Long-Term Cohort Study.
Meier MA; Ottiger M; Vögeli A; Steuer C; Bernasconi L; Thomann R; Christ-Crain M; Henzen C; Hoess C; Zimmerli W; Huber A; Mueller B; Schuetz P
Lung; 2017 Jun; 195(3):303-311. PubMed ID: 28434116
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of tryptophan catabolism in Hodgkin lymphoma.
Masaki A; Ishida T; Maeda Y; Ito A; Suzuki S; Narita T; Kinoshita S; Takino H; Yoshida T; Ri M; Kusumoto S; Komatsu H; Inagaki H; Ueda R; Choi I; Suehiro Y; Iida S
Cancer Sci; 2018 Jan; 109(1):74-83. PubMed ID: 29080383
[TBL] [Abstract][Full Text] [Related]
20. Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
Botticelli A; Cerbelli B; Lionetto L; Zizzari I; Salati M; Pisano A; Federica M; Simmaco M; Nuti M; Marchetti P
J Transl Med; 2018 Aug; 16(1):219. PubMed ID: 30081936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
